Purdue’s Philip Low Discusses Folic Acid-Based Targeted siRNA Delivery

The technology is based on the presence of folate receptors only on certain pathogenic cells such as cancer cells and activated macrophages. Low and colleagues still must overcome the hurdle of endosomal escape before the technology can be applied to siRNA delivery, however.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.